well neurontonin is less attractive than they thought, the analysts say the drugs are still effective. if they can control the diarrhea problem it could have an upside. given that puma is already studying their drug in combination with imodium, the bulls at j.p. morgan think that this compound's benefits will outweigh the safety risks and they're betting the fda will agree with them. ultimately these guys believe it could do $2-billion in peak sales from breast cancer alone. remember it's being studied in solid tumors and nonsmall cell lung cancer. that means the upside could be enormous given that puma is a $3 billion company. where do i come down? this is tough. i like what i hear but right now puma feels to me like the quintessential high-risk high-reward biotech. if the upcoming data is positive and the companies can convince doctors to view neurontonin as less problems with die korea, the stock could rocket higher. if things don't go well, the down side could be enormous from these levels. so i ask you, wouldn't it be better to go by a cell gene, also up 4 today but with a heck o